- Home
- OBAI vs ACRS Comparison
OBAI vs ACRS Comparison
Compare OBAI & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OBAI | ACRS |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.0M | 314.2M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | OBAI | ACRS |
|---|---|---|
| Price | $6.49 | $3.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 73.3K | ★ 3.1M |
| Earning Date | 01-01-0001 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $9,794,000.00 | ★ $15,742,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.18 | N/A |
| 52 Week Low | $5.77 | $1.05 |
| 52 Week High | $38.50 | $4.89 |
Technical Indicators
Market Signals| Indicator | OBAI | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 48.83 |
| Support Level | N/A | $3.33 |
| Resistance Level | N/A | $3.78 |
| Average True Range (ATR) | 0.00 | 0.33 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 0.00 | 3.31 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.